Cargando…
Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
BACKGROUND: We evaluated the effects of once-daily extended-release quetiapine fumarate (quetiapine XR) on patient-reported outcomes in generalized anxiety disorder (GAD). METHODS: This is a report of a pooled analysis from three acute 8-week, randomized, placebocontrolled, fixed-dose (50, 150, 300...
Autores principales: | Endicott, Jean, Svedsäter, Henrik, Locklear, Julie C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404593/ https://www.ncbi.nlm.nih.gov/pubmed/22848184 http://dx.doi.org/10.2147/NDT.S32320 |
Ejemplares similares
-
Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili, Nizar
Publicado: (2012) -
The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens, Joseph
Publicado: (2011) -
A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
por: Wang, Gang, et al.
Publicado: (2014) -
The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese population
por: Pan, Pei-Yin, et al.
Publicado: (2015) -
Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study
por: Chen, Yi-Chih, et al.
Publicado: (2012)